Jamison Private Wealth Management, Inc. Krystal Biotech, Inc. Transaction History
Jamison Private Wealth Management, Inc.
- $657 Billion
- Q3 2024
A detailed history of Jamison Private Wealth Management, Inc. transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Jamison Private Wealth Management, Inc. holds 150 shares of KRYS stock, worth $26,715. This represents 0.0% of its overall portfolio holdings.
Number of Shares
150
Previous 150
-0.0%
Holding current value
$26,715
Previous $27.5 Million
0.87%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding KRYS
# of Institutions
310Shares Held
24.4MCall Options Held
483KPut Options Held
364K-
Black Rock Inc. New York, NY3.95MShares$703 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.85MShares$508 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.62MShares$467 Million7.18% of portfolio
-
State Street Corp Boston, MA1.45MShares$259 Million0.01% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA988KShares$176 Million9.67% of portfolio
About Krystal Biotech, Inc.
- Ticker KRYS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,664,300
- Market Cap $4.57B
- Description
- Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...